Obtaining tissue specimens from patients with progressed disease status to perform molecular analysis can be challenging. Liquid biopsy-based approaches as an alternative testing method, through use of circulating cell-free tumor DNA (ccfDNA) isolated from plasma samples, has improved in the last couple of years, providing an option when tissue is limited or not available.

Additionally, liquid biopsy might be used as a tool for follow-up analysis to check for tumor recurrence and/or resistance to therapy. Beyond its utility for comprehensive genomic profiling (CGP), liquid biopsy-based approaches also provide a path to enable follow up analysis to track disease progression and/ or response to therapy. PGDx elio™ plasma resolve, a highly targeted approach that enables interrogation of 30 genes with MSI-H reporting, and PGDx elio™ plasma complete assay, a more comprehensive approach covering more than 50 genes and reports on bTMB in addition to MSI, were implemented in our laboratory for identifying mutations in liquid biopsy specimens. 

To assess performance of these assays, we compared the PGDx elio products with other techniques. We were able to show concordance among the assays, and in some cases, the PGDx elio assays outperformed other techniques with mutation detection. 

The goal of this webinar is to share the learnings around the ease of onboarding a liquid biopsy solution in a laboratory setting and to review the performance of two liquid biopsy assays versus other molecular testing techniques.

Webinar Learning Objectives:

• How to implement a comprehensive in-house liquid biopsy-based CGP assay within a laboratory setting
• The value of incorporating different liquid biopsy-based methodologies to thoroughly interrogate key biomarkers in precision oncology and key considerations for implementation.
• Sample and data ownership opens pathways to explore research opportunities.